Dr Jezek’s PEPTalk presentation, entitled ‘Controlling Aggregation of a Range of Novel Biopharmaceutical Product Modalities’, will summarise several case studies demonstrating the capability of Arecor’s formulation technology platform, Arestat™, to develop differentiated biopharmaceutical products and explain some of the key scientific principles that underpin this technology.
Date: Friday, 24 January 2020
Time: 10:05-10:35
Session: Protein Aggregation and Emerging Analytical Tools
Location: Hilton San Diego Bayfront, San Diego, CA
Aggregation is one of the main technical hurdles in developing high-value biopharmaceutical products. This is particularly the case with a number of novel product constructs, including bispecific antibodies, antibody fragments or viral vectors used in gene therapy. Aggregated products may result in undesirable immune response or they may affect the therapeutic efficacy. Therefore, the level of aggregation in biopharmaceutical compositions must be maintained to a minimum. Arecor has developed a proprietary formulation technology, Arestat™, that enables superior biopharmaceutical products via minimising the rate of aggregation as well as other degradation pathways. Application of the technology allows development of safe and convenient products that would otherwise not be achievable using conventional approaches to formulation.